Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG1827 plus anti-PD-1/PD-L1 antibody and bevacizumab in advanced solid tumors (Ib/II)
CTR20263075Phase 2Active
- Sponsor
- Shangjian Bio
- Start
- Sep 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SG1827 in Non-hematologic malignancy, sponsored by Shangjian Bio. Started Sep 2026; status: active.
02
Drugs
SG1827
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on CTR20263075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263075.